🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 16 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/02/2011 | 39,02 | 39,20 | 38,20 | 38,33 | -2,86% | 2,56% | 2.090.900 |
| 04/02/2011 | 38,88 | 39,92 | 38,51 | 39,46 | +1,70% | 3,63% | 2.939.500 |
| 03/02/2011 | 38,51 | 39,10 | 38,50 | 38,80 | -0,44% | 1,56% | 2.416.700 |
| 02/02/2011 | 38,93 | 39,68 | 38,90 | 38,97 | +0,31% | 2,00% | 2.114.300 |
| 01/02/2011 | 39,15 | 39,50 | 38,83 | 38,85 | -0,10% | 1,71% | 1.991.000 |
| 31/01/2011 | 38,94 | 39,16 | 38,34 | 38,89 | -0,31% | 2,11% | 2.495.500 |
| 28/01/2011 | 39,86 | 40,44 | 38,66 | 39,01 | -0,96% | 4,47% | 2.319.800 |
| 27/01/2011 | 39,75 | 40,04 | 39,23 | 39,39 | -0,91% | 2,04% | 1.924.100 |
| 26/01/2011 | 40,36 | 40,63 | 39,57 | 39,75 | -1,12% | 2,63% | 1.913.500 |
| 25/01/2011 | 40,30 | 40,88 | 40,00 | 40,20 | -0,57% | 2,18% | 1.479.700 |
| 24/01/2011 | 40,00 | 40,62 | 39,78 | 40,43 | +0,92% | 2,10% | 1.613.400 |
| 21/01/2011 | 39,94 | 40,12 | 39,70 | 40,06 | +0,40% | 1,05% | 2.075.100 |
| 20/01/2011 | 39,34 | 40,12 | 39,23 | 39,90 | +1,14% | 2,26% | 1.790.100 |
| 19/01/2011 | 39,92 | 39,97 | 39,20 | 39,45 | -1,37% | 1,93% | 2.623.900 |
| 18/01/2011 | 39,46 | 40,11 | 39,46 | 40,00 | +1,47% | 1,65% | 2.977.300 |
| 14/01/2011 | 38,56 | 39,42 | 38,32 | 39,42 | +2,26% | 2,85% | 3.006.600 |
| 13/01/2011 | 37,31 | 38,55 | 37,19 | 38,55 | +3,60% | 3,65% | 2.431.000 |
| 12/01/2011 | 37,04 | 37,28 | 36,59 | 37,21 | +1,14% | 1,86% | 1.253.200 |
| 11/01/2011 | 37,66 | 37,85 | 36,52 | 36,79 | +1,38% | 3,53% | 2.442.200 |
| 10/01/2011 | 35,95 | 36,54 | 35,71 | 36,29 | +0,36% | 2,31% | 2.163.300 |
| 07/01/2011 | 36,26 | 36,36 | 35,72 | 36,16 | -0,11% | 1,77% | 1.462.800 |
| 06/01/2011 | 36,60 | 36,80 | 36,18 | 36,20 | -1,74% | 1,69% | 1.548.900 |
| 05/01/2011 | 35,56 | 37,07 | 35,56 | 36,84 | +3,80% | 4,25% | 2.866.800 |
| 04/01/2011 | 36,02 | 36,22 | 35,32 | 35,49 | -1,39% | 2,50% | 1.229.300 |
| 03/01/2011 | 35,20 | 36,23 | 35,19 | 35,99 | +2,74% | 2,95% | 1.752.900 |
| 31/12/2010 | 35,37 | 35,44 | 34,97 | 35,03 | -0,88% | 1,33% | 938.600 |
| 30/12/2010 | 35,25 | 35,49 | 35,22 | 35,34 | -0,37% | 0,77% | 630.100 |
| 29/12/2010 | 35,34 | 36,04 | 35,28 | 35,47 | +0,60% | 2,15% | 1.055.900 |
| 28/12/2010 | 35,26 | 35,45 | 35,07 | 35,26 | +0,00% | 1,08% | 818.800 |
| 27/12/2010 | 35,32 | 35,47 | 34,69 | 35,26 | -0,37% | 2,21% | 1.004.600 |